Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Guanidine hydrochloride** is a small molecule pharmaceutical agent used primarily to reduce symptoms of muscle weakness and fatigability in patients with Lambert-Eaton myasthenic syndrome (LEMS, also called myasthenic syndrome of Eaton-Lambert)[1][2][4][5]. It is chemically the hydrochloride salt of guanidine (aminomethanamidine) and is often encountered as a white crystalline powder highly soluble in water[1][7]. Its principal mechanism is thought to involve **enhancement of acetylcholine release** at nerve terminals following a nerve impulse[1][5][9]. Additionally, it slows rates of depolarization and repolarization in muscle cell membranes, thereby improving neuromuscular transmission[1][5][9]. Guanidine hydrochloride is not indicated for myasthenia gravis, and use is limited due to side effects and the risk of fatal, dose-related bone marrow suppression[1][2][5]. It is sometimes used in biochemistry as a chaotropic agent for protein denaturation, unrelated to its pharmaceutical use[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on guanidine hydrochloride.